Login to Your Account



Other News To Note


Wednesday, February 15, 2012
• Gedeon Richter plc, of Budapest, Hungary, and Forest Laboratories Inc., of New York, reported top-line results from a Phase III trial of cariprazine (RHG-188), an antipsychotic agent, in patients with acute mania associated with bipolar I disorder. For the primary endpoint, the Young Mania Rating Scale, data showed cariprazine-treated patients experienced significant improvements in symptoms compared to those in the placebo arm, observed as early as day five of treatment and at each subsequent time point studied.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription